Literature DB >> 24407486

Impact of anti-tumor necrosis factor alpha antibodies administered to pregnant women with inflammatory bowel disease on long-term outcome of exposed children.

Martin Bortlik1, Dana Duricova, Nadezda Machkova, Jana Kozeluhova, Pavel Kohout, Ludek Hrdlicka, Marianna Durilova, Katarina Mitrova, Ondrej Hradsky, Jiri Bronsky, Karin Malickova, Milan Lukas.   

Abstract

BACKGROUND: Prenatal exposure to anti-tumor necrosis factor α (TNF-α) antibodies seems to be safe for fetal development. Data on long-term outcome of exposed children are missing. Our aim was to assess long-term postnatal development of children exposed to anti-TNF-α during pregnancy.
METHODS: Consecutive children aged ≥ 12 months exposed to anti-TNFs prenatally for maternal inflammatory bowel disease in 3 centers in the Czech Republic were enrolled. Data on psychomotor development, infections, antibiotics, vaccination, and allergy were retrospectively obtained from mothers, treating pediatricians, and children's vaccination cards. Furthermore, standardized laboratory tests on humoral and cellular immunity were performed.
RESULTS: Twenty-five children exposed to biologicals were included (median age, 34 mo; range, 14-70 mo). All children had normal growth, and all but 1 had normal psychomotor development. Majority (80%) experienced at least 1 infection (mainly respiratory), and 60% of infants received antibiotics, 32% of those within the first year of life. Vaccination was undertaken according to vaccination protocol to 23 infants (92%). Fifteen children also had tuberculosis vaccination without serious complication. Immunological investigation was performed with 17 children (68%). Cellular immunity was normal in all infants, and 7 children had mild decrease in IgA and/or IgG immunoglobulins without clinical significance. All children had a detectable serologic response to vaccination.
CONCLUSIONS: Exposure to anti-TNF-α antibodies seems to be safe for growth and psychomotor development of children, although clinical significance of relatively high frequency of infections and antibiotic use among infants remains questionable because of the lack of a control group. Continuous follow-up of exposed children is absolutely warranted.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24407486     DOI: 10.1097/01.MIB.0000440984.86659.4f

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  13 in total

1.  The Effect of Maternal Peripartum Anti-TNFα Use on Infant Immune Response.

Authors:  Sarah Sheibani; Russell Cohen; Sunanda Kane; Marla Dubinsky; Joseph A Church; Uma Mahadevan
Journal:  Dig Dis Sci       Date:  2016-01-02       Impact factor: 3.199

Review 2.  Management of the pregnant inflammatory bowel disease patient on anti-tumour necrosis factor: state of the art and future directions.

Authors:  Yvette Leung; Remo Panaccione; Subrata Ghosh; Cynthia H Seow
Journal:  Can J Gastroenterol Hepatol       Date:  2014-08-06

3.  Influence of anti-tumor necrosis factor-alpha therapy to pregnant inflammatory bowel disease women and their children's immunity.

Authors:  Ko Eun Lee; Sung-Ae Jung; Sang Hyoung Park; Chang Mo Moon; So Yeon Shim; Eun Soo Kim; Su Jin Cho; Seong-Eun Kim; Kwang Bum Cho; Suk-Kyun Yang
Journal:  Intest Res       Date:  2019-02-08

4.  Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies.

Authors:  Kim A Papp; Boulos Haraoui; Deepali Kumar; John K Marshall; Robert Bissonnette; Alain Bitton; Brian Bressler; Melinda Gooderham; Vincent Ho; Shahin Jamal; Janet E Pope; A Hillary Steinhart; Donald C Vinh; John Wade
Journal:  J Cutan Med Surg       Date:  2018-11-21       Impact factor: 2.092

Review 5.  The Impact of Inflammatory Bowel Disease on Pregnancy and the Fetus: A Literature Review.

Authors:  Hira Pervez; Norina Usman; Munis M Ahmed; Mydah S Hashmi
Journal:  Cureus       Date:  2019-09-13

Review 6.  Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)-Part 1: Live Vaccines.

Authors:  Eric I Benchimol; Frances Tse; Matthew W Carroll; Jennifer C deBruyn; Shelly A McNeil; Anne Pham-Huy; Cynthia H Seow; Lisa L Barrett; Talat Bessissow; Nicholas Carman; Gil Y Melmed; Otto G Vanderkooi; John K Marshall; Jennifer L Jones
Journal:  J Can Assoc Gastroenterol       Date:  2021-07-29

7.  The safety of drugs for inflammatory bowel disease during pregnancy and breastfeeding: the DUMBO registry study protocol of GETECCU.

Authors:  María Chaparro; María G Donday; Francisco Abad-Santos; Francisco Javier Martín de Carpi; Miguel Ángel Maciá-Martínez; Dolores Montero; Diana Acosta; Yanire Brenes; Javier P Gisbert
Journal:  Therap Adv Gastroenterol       Date:  2021-06-03       Impact factor: 4.409

Review 8.  A guide to prepare patients with inflammatory bowel diseases for anti-TNF-α therapy.

Authors:  Júlio Maria Fonseca Chebli; Pedro Duarte Gaburri; Liliana Andrade Chebli; Tarsila Campanha da Rocha Ribeiro; André Luiz Tavares Pinto; Orlando Ambrogini Júnior; Adérson Omar Mourão Cintra Damião
Journal:  Med Sci Monit       Date:  2014-03-26

Review 9.  Antirheumatic drugs and reproduction in women and men with chronic arthritis.

Authors:  Chiara Bazzani; Laura Andreoli; Michele Agosti; Cecilia Nalli; Angela Tincani
Journal:  RMD Open       Date:  2015-08-15

Review 10.  The use and impact of monoclonal antibody biologics during pregnancy.

Authors:  Anne Pham-Huy; Karina A Top; Cora Constantinescu; Cynthia H Seow; Darine El-Chaâr
Journal:  CMAJ       Date:  2021-07-26       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.